New nasal device could make COPD breathing treatments easier
NCT ID NCT02812979
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether giving the breathing drug salbutamol through a high-flow nasal device works as well as the usual mask method for people with COPD. 25 adults with COPD took part. The goal was to see if the new method is not worse at improving lung function.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- salbutamol
- What this could lead to
- If it works, this could offer a more comfortable way to deliver breathing medication for COPD patients.
- What could go wrong
- This is a small, early study with only 25 participants, so results may not apply to everyone. It only tests if the new method is not worse than the usual one, not if it is better.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
25 people
The number who actually took part.
- Start date
-
Jun 2016
- Finished
-
Apr 2018
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * adults * Patient with chronic obstructive pulmonary disease * Patients, when performing lung function tests performed outside of the study : 1. A report FEV / FVC less than 60% prior to bronchodilator treatment AND 2. A positive reversal test defined by FEV variation of over 12 % and 200 mL after administration of inhaled salbutamol * Patients affiliated to social security scheme * Informed consent signed by the patient Exclusion Criteria: * Exacerbation of chronic obstructive pulmonary disease during * Uncontrolled asthma * Pneumothorax current or recent ( \< 2 months) * Pleural aspiration or biopsy , trans - bronchial biopsies and / or bronchoalveolar lavage in the preceding 48h * hemoptysis in progress * Patient under guardianship or trusteeship safeguard justice * Pregnant or breastfeeding women or parturient woman * Known allergy or intolerance to salbutamol
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic obstructive pulmonary disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Service de Réanimation Polyvalente
Tours, 37044, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a COPD flare stun the heart? study watches for hidden strain
- Can better training get doctors to talk about what matters most to dying veterans?
- Can an injected antibody calm inflamed lungs and cut COPD flare-ups?
- Detailed lung scans could map COPD damage more precisely
- Can AI help nurses guide At-Risk seniors to better care and lower costs?
- Fine-Mist inhalers aim to reach deep lungs in COPD